Fast TIL therapy for cancers that have spread to the pleura, including mesothelioma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This first-in-human Phase 1 approach expands pleural infiltrating T cells (PIT) from a patient’s drained pleural fluid at a local GMP facility and delivers the product directly into the pleural space. Patients undergo outpatient lymphodepleting chemotherapy before intrapleural infusion of the locally manufactured Adoptive Cellular Therapy (ACT) product, followed by two days of intrapleural IL-2 to stimulate the transferred cells while limiting systemic exposure. The protocol uses a pleural catheter for both infusion and IL-2 administration and monitors safety and local tumor effects. Ancillary laboratory studies on pleural fluid collected before and after treatment will explore mechanisms of response or resistance.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with symptomatic, biopsy-proven malignant to the pleura, or mesothelioma with pleural effusions. Patients must have received and be refractory to available standard of care (SOC) therapy specific to their cancer type and must have exhausted or failed available standard of care with clinical benefit.
2. Patients will be ≥ 18 and \< 80 years of age.
3. Female patients of childbearing potential must have a negative urine or serum pregnancy test and if sexually active must use an acceptable method of contraception, including abstinence, a barrier method (diaphragm or condom), an injectable contraceptive (such as Depo-Provera), or an oral contraceptive. Active contraception should continue for at least 12 months after ACT administration.

   Male participants must be willing to practice birth control from the time of enrollment on this study and for 4 months after receiving the preparative regimen.
4. Cardiac ejection fraction ≥ 0.45 by MUGA or echocardiography.
5. No requirement for supplemental oxygen and no dyspnea immediately after effusion drainage.
6. ECOG Performance Status 0 or 1.
7. Patients must have an expected survival \> 12 weeks.
8. Patients must be able to comprehend the risks and methods used in this clinical trial and independently consent to participate.
9. Patients must consent to collection of demographic and clinical data.

Exclusion Criteria:

1. Infection with HIV and active viral replication. Patients with an undetectable viral load on Anti-retroviral Therapy (ART) can be considered for participation on this protocol.
2. Infection with hepatitis B and active viral replication.
3. Infection with hepatitis C and active viral replication.
4. Patients currently being treated for bacterial, fungal or viral infection.
5. Documented myocardial infarction within 6 months of study participation and/or symptomatic coronary artery or valvular disease or uncontrolled arrhythmia.
6. Investigational drug use within 30 days before effusion collection.
7. Cytotoxic anti-cancer or radiation therapy administration within 2 weeks of effusion collection. The exclusion does not apply to patients receiving monoclonal antibody therapy targeting immune checkpoint molecules.
8. Corticosteroid therapy \> 10 mg of prednisone (biological equivalent) daily within 2 weeks before effusion collection.
9. Immunosuppressive therapy that cannot be stopped for 4 weeks prior to effusion collection as deemed by the prescribing physician.
10. Laboratory abnormalities that indicate clinically significant hematological, hepatobiliary, or renal disease:

    AST/SGOT \> 2.0 times the upper limit of normal ALT/SGPT \> 2.0 times the upper limit of normal Total bilirubin \> 2.0 times the upper limit of normal, unless patient has Gilbert Syndrome (\>3.0 times the upper limit of normal) Hemoglobin \< 8 gm/dL or dependent upon transfusion to maintain ≥ 8 gm/dL White blood cell count \< 2,000/mm3 Platelet count \< 100,000/mm3 or dependent upon transfusion to maintain ≥ 100,000 mm3 Creatinine \> 2.0 times the upper limit of normal or calculated creatinine clearance ≤ 40 mL/min.
11. Pregnant or lactating females.
12. Prior solid organ transplantation
13. Patients who, in the opinion of the Investigator, will be non-compliant with study schedules or procedures.
14. Patients who belong to a vulnerable population such as the homeless, the developmentally disabled and prisoners or have any condition that impairs their ability to provide informed consent or comply with study schedules or procedures.
15. Patients with documented anaphylaxis as a result of penicillin allergy.

Where it's running

• AHN West Penn Hospital
  Pittsburgh, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Patrick Wagner, MD — Allegheny Health Network
• Study coordinator: Patrick Wagner, MD
• Email: patrick.wagner@ahn.org
• Phone: 412-359-3731

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Fast TIL therapy for cancers that have spread to the pleura

  This treatment will try a patient's own pleural T cells, grown quickly in the lab and given into the chest with local IL-2, for adults whose cancer has spread to the pleura or for pleural mesothelioma.

  Recruiting Phase 1 Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Pittsburgh, Pennsylvania · NCT07192900

• Does turning patients during doxycycline pleurodesis improve success and comfort for malignant pleural effusion?

  We will test whether turning people during doxycycline pleurodesis helps seal cancer-related pleural fluid and improves comfort.

  Recruiting Ain Shams University · Cairo · NCT07147270

• Local anesthesia thoracoscopy for diagnosing pleural effusion

  This study tests if using local anesthesia during a thoracoscopy can help diagnose suspected cancer-related fluid buildup in the chest faster and more comfortably than standard tests.

  Recruiting National and Kapodistrian University of Athens · Athens, Attica · NCT06946498

• MT027 treatment for patients with pleural malignant tumors

  This study is testing a new treatment called MT027 for patients with pleural malignant tumors to see if it's safe and how well it works after they have already received standard treatment.

  Recruiting Phase 1 Suzhou Maximum Bio-tech Co., Ltd. · Beijing · NCT06726564

• Evaluating ISM6331 for advanced malignant mesothelioma and solid tumors

  This study is testing a new drug called ISM6331 to see if it is safe and effective for people with advanced malignant mesothelioma and other solid tumors who haven't had success with standard treatments.

  Recruiting at 10 sites Phase 1/2 InSilico Medicine Hong Kong Limited · Denver, Colorado and 9 other locations · NCT06566079

• Additional chemotherapy after surgery for malignant peritoneal mesothelioma

  This study is testing whether giving chemotherapy directly into the abdomen or through an IV after surgery helps people with malignant peritoneal mesothelioma do better.

  Recruiting at 9 sites Phase 2 Memorial Sloan Kettering Cancer Center · Chicago, Illinois and 12 other locations · NCT06057935

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.